CATPB

CATPB
Identifiers
	IUPAC name (3S)-3-[[2-(3-chlorophenyl)acetyl]amino]-4-[4-(trifluoromethyl)phenyl]butanoic acid;
CAS Number	1322598-09-3;
PubChem CID	53308747;
IUPHAR/BPS	6487;
ChemSpider	34980782;
ChEMBL	ChEMBL5412634;
Chemical and physical data
Formula	C19H17ClF3NO3
Molar mass	399.79 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC(=CC(=C1)Cl)CC(=O)N[C@@H](CC2=CC=C(C=C2)C(F)(F)F)CC(=O)O;
	InChI InChI=1S/C19H17ClF3NO3/c20-15-3-1-2-13(8-15)10-17(25)24-16(11-18(26)27)9-12-4-6-14(7-5-12)19(21,22)23/h1-8,16H,9-11H2,(H,24,25)(H,26,27)/t16-/m0/s1; Key:QOSIJVVNNGXEKE-INIZCTEOSA-N;

CATPB is an experimental drug which acts as a potent and selective antagonist for the free fatty acid receptor FFAR2 (GPR43), and is used for research into the function of this receptor.^[1]^[2]^[3]^[4]^[5]^[6]

References

^ Park BO, Kim SH, Kong GY, Kim DH, Kwon MS, Lee SU, et al. (January 2016). "Selective novel inverse agonists for human GPR43 augment GLP-1 secretion". European Journal of Pharmacology. 771: 1–9. doi:10.1016/j.ejphar.2015.12.010. PMID 26683635.
^ Mårtensson J, Holdfeldt A, Sundqvist M, Gabl M, Kenakin TP, Björkman L, et al. (December 2018). "Neutrophil priming that turns natural FFA2R agonists into potent activators of the superoxide generating NADPH-oxidase". Journal of Leukocyte Biology. 104 (6): 1117–1132. doi:10.1002/JLB.2A0318-130RR. PMID 30134499.
^ Højgaard Hansen A, Christensen HB, Pandey SK, Sergeev E, Valentini A, Dunlop J, et al. (November 2021). "Structure-Activity Relationship Explorations and Discovery of a Potent Antagonist for the Free Fatty Acid Receptor 2". ChemMedChem. 16 (21): 3326–3341. doi:10.1002/cmdc.202100356. PMID 34288488.
^ Miyasato S, Iwata K, Mura R, Nakamura S, Yanagida K, Shindou H, et al. (January 2023). "Constitutively active GPR43 is crucial for proper leukocyte differentiation". FASEB Journal. 37 (1): e22676. doi:10.1096/fj.202201591R. PMID 36468834.
^ Valentini A, Schultz-Knudsen K, Højgaard Hansen A, Tsakoumagkou A, Jenkins L, Christensen HB, et al. (May 2023). "Discovery of Potent Tetrazole Free Fatty Acid Receptor 2 Antagonists". Journal of Medicinal Chemistry. 66 (9): 6105–6121. doi:10.1021/acs.jmedchem.2c01935. PMC 10547238. PMID 37129317.
^ Muradás TC, Freitas RD, Gonçalves JI, Xavier FA, Marinowic DR (2024). "Potential antitumor effects of short-chain fatty acids in breast cancer models". American Journal of Cancer Research. 14 (5): 1999–2019. doi:10.62347/ETUQ6763. PMC 11162650. PMID 38859825.

[1] Park BO, Kim SH, Kong GY, Kim DH, Kwon MS, Lee SU, et al. (January 2016). "Selective novel inverse agonists for human GPR43 augment GLP-1 secretion". European Journal of Pharmacology. 771: 1–9. doi:10.1016/j.ejphar.2015.12.010. PMID 26683635.

[2] Mårtensson J, Holdfeldt A, Sundqvist M, Gabl M, Kenakin TP, Björkman L, et al. (December 2018). "Neutrophil priming that turns natural FFA2R agonists into potent activators of the superoxide generating NADPH-oxidase". Journal of Leukocyte Biology. 104 (6): 1117–1132. doi:10.1002/JLB.2A0318-130RR. PMID 30134499.

[3] Højgaard Hansen A, Christensen HB, Pandey SK, Sergeev E, Valentini A, Dunlop J, et al. (November 2021). "Structure-Activity Relationship Explorations and Discovery of a Potent Antagonist for the Free Fatty Acid Receptor 2". ChemMedChem. 16 (21): 3326–3341. doi:10.1002/cmdc.202100356. PMID 34288488.

[4] Miyasato S, Iwata K, Mura R, Nakamura S, Yanagida K, Shindou H, et al. (January 2023). "Constitutively active GPR43 is crucial for proper leukocyte differentiation". FASEB Journal. 37 (1): e22676. doi:10.1096/fj.202201591R. PMID 36468834.

[5] Valentini A, Schultz-Knudsen K, Højgaard Hansen A, Tsakoumagkou A, Jenkins L, Christensen HB, et al. (May 2023). "Discovery of Potent Tetrazole Free Fatty Acid Receptor 2 Antagonists". Journal of Medicinal Chemistry. 66 (9): 6105–6121. doi:10.1021/acs.jmedchem.2c01935. PMC 10547238. PMID 37129317.

[6] Muradás TC, Freitas RD, Gonçalves JI, Xavier FA, Marinowic DR (2024). "Potential antitumor effects of short-chain fatty acids in breast cancer models". American Journal of Cancer Research. 14 (5): 1999–2019. doi:10.62347/ETUQ6763. PMC 11162650. PMID 38859825.

[1]

[2]

[3]

[4]

[5]

[6]